BR112014032560A2 - células para produzir iduronato-2-sulfatase recombinante - Google Patents

células para produzir iduronato-2-sulfatase recombinante

Info

Publication number
BR112014032560A2
BR112014032560A2 BR112014032560-0A BR112014032560A BR112014032560A2 BR 112014032560 A2 BR112014032560 A2 BR 112014032560A2 BR 112014032560 A BR112014032560 A BR 112014032560A BR 112014032560 A2 BR112014032560 A2 BR 112014032560A2
Authority
BR
Brazil
Prior art keywords
cells
present
recombinant
adaptable
protein
Prior art date
Application number
BR112014032560-0A
Other languages
English (en)
Other versions
BR112014032560B1 (pt
Inventor
Bolgog Ferenc
Heartlein Mike
Original Assignee
Shire Human Genetic Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies, Inc. filed Critical Shire Human Genetic Therapies, Inc.
Publication of BR112014032560A2 publication Critical patent/BR112014032560A2/pt
Publication of BR112014032560B1 publication Critical patent/BR112014032560B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

abstract the present invention provides, among other things, methods and compositions for production of recombinant i2s protein with improved potency and activity using cells co-express i2s and fge protein. in some embodiments, cells according to the present invention are engineered to simultaneously over-express recombinant i2s and fge proteins. cells according to the invention are adaptable to various cell culture conditions. in some embodiments, cells of the present invention adaptable to a large-scale suspension serum-free culture. tradução do resumo resumo "células para produzir iduronato-2-sulfatase recombinante" a presente invenção fornece, entre outras coisas, métodos e composições para produção de proteína i2s recombinante com potência e atividade melhoradas usando células que coexpressam proteína i2s e fge. em algumas modalidades, as células de acordo com a presente invenção são engenheiradas para simultaneamente superexpressarem proteínas i2s e fge recombinantes. as células de acordo com a invenção são adaptáveis a diversas condições de cultura de célula. em algumas modalidades, as células da presente invenção são adaptáveis a uma cultura livre de soro de suspensão em grande escala.
BR112014032560-0A 2012-06-29 2013-06-28 Método para produzir a proteína iduronato-2-sulfatase (i2s) recombinante BR112014032560B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666719P 2012-06-29 2012-06-29
US61/666,719 2012-06-29
PCT/US2013/048571 WO2014005019A2 (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Publications (2)

Publication Number Publication Date
BR112014032560A2 true BR112014032560A2 (pt) 2018-03-06
BR112014032560B1 BR112014032560B1 (pt) 2022-04-26

Family

ID=49778522

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032560-0A BR112014032560B1 (pt) 2012-06-29 2013-06-28 Método para produzir a proteína iduronato-2-sulfatase (i2s) recombinante

Country Status (27)

Country Link
US (3) US9150841B2 (pt)
EP (1) EP2874649B1 (pt)
JP (3) JP6067849B2 (pt)
KR (1) KR101710487B1 (pt)
CN (2) CN107267460A (pt)
AU (3) AU2013282400B2 (pt)
BR (1) BR112014032560B1 (pt)
CA (1) CA2877521C (pt)
CL (1) CL2014003568A1 (pt)
CO (1) CO7240394A2 (pt)
CR (1) CR20140586A (pt)
DO (1) DOP2014000298A (pt)
EA (2) EA035511B1 (pt)
ES (1) ES2718346T3 (pt)
GT (1) GT201400302A (pt)
HK (2) HK1209331A1 (pt)
IL (3) IL236343A (pt)
MX (2) MX366155B (pt)
MY (2) MY189314A (pt)
NZ (2) NZ734670A (pt)
PE (1) PE20150957A1 (pt)
PH (2) PH12014502868A1 (pt)
SG (2) SG11201408702VA (pt)
TR (1) TR201904435T4 (pt)
UA (1) UA118955C2 (pt)
WO (1) WO2014005019A2 (pt)
ZA (1) ZA201409396B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HRP20220796T1 (hr) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP4148122A1 (en) * 2012-05-02 2023-03-15 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
US9550972B2 (en) 2014-09-29 2017-01-24 General Electric Company Devices, systems and methods for automated cell culturing
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
CA3001003A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
JP7060235B2 (ja) * 2018-05-18 2022-04-26 国立大学法人広島大学 変異型イズロン酸－２－スルファターゼの機能回復薬剤のスクリーニング方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
DE69531044T2 (de) 1994-03-16 2003-12-04 The Regents Of The University Of California, Alameda Behandlung von entzündung durch die gabe von spezifischen sulfatase-enzymen und/oder inhibitoren der sulfatierung
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
ES2281342T3 (es) 1999-04-26 2007-10-01 Genentech, Inc. Proceso de cultivo de celulas para la produccion de glicoproteinas.
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
CA2400034A1 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
JP2003527851A (ja) 2000-03-17 2003-09-24 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ７つのヒト卵巣および卵巣癌関連タンパク質
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
ES2545067T3 (es) 2002-04-26 2015-09-08 Genentech, Inc. Purificación de proteínas basada en la no afinidad
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
US7541164B2 (en) 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8227212B2 (en) 2003-02-11 2012-07-24 Shire Human Genetic Therapies, Inc. Cell that expresses a sulfatase and a formylglycine generating enzyme
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
US7691611B2 (en) 2005-06-03 2010-04-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
CN105274072A (zh) * 2008-01-18 2016-01-27 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
EP2485833A2 (en) * 2009-10-09 2012-08-15 Dow Global Technologies LLC Adiabatic plug flow reactors and process for producing a chlorinated and/or fluorinated propene and higher alkene
JPWO2011108451A1 (ja) 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
NZ702808A (en) 2010-06-25 2016-08-26 Shire Human Genetic Therapies Methods and compositions for cns delivery of iduronate-2-sulfatase
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase

Also Published As

Publication number Publication date
JP6302499B2 (ja) 2018-03-28
HK1209651A1 (en) 2016-04-08
AU2013282400B2 (en) 2016-02-04
ZA201409396B (en) 2018-05-30
JP6755272B2 (ja) 2020-09-16
JP6067849B2 (ja) 2017-01-25
EP2874649A4 (en) 2016-05-04
WO2014005019A2 (en) 2014-01-03
MY189314A (en) 2022-02-04
IL274266A (en) 2020-06-30
EP2874649A2 (en) 2015-05-27
MY157086A (en) 2016-04-19
SG11201408702VA (en) 2015-02-27
MX336716B (es) 2016-01-28
CA2877521C (en) 2021-06-01
US20140004593A1 (en) 2014-01-02
EA202090805A1 (ru) 2020-11-30
MX366155B (es) 2019-06-28
US20180010108A1 (en) 2018-01-11
EP2874649B1 (en) 2019-01-02
KR20150030242A (ko) 2015-03-19
JP2016105737A (ja) 2016-06-16
NZ734670A (en) 2019-12-20
CN104540517A (zh) 2015-04-22
US9719074B2 (en) 2017-08-01
PH12016500011A1 (en) 2019-08-14
CR20140586A (es) 2015-04-06
PH12014502868B1 (en) 2015-02-23
IL236343A (en) 2017-10-31
PH12014502868A1 (en) 2015-02-23
TR201904435T4 (tr) 2019-05-21
EA035511B1 (ru) 2020-06-26
UA118955C2 (uk) 2019-04-10
AU2016200460B2 (en) 2017-11-02
NZ703137A (en) 2017-08-25
PE20150957A1 (es) 2015-07-15
AU2013282400A1 (en) 2015-01-29
HK1209331A1 (en) 2016-04-01
WO2014005019A3 (en) 2014-02-27
JP2018088933A (ja) 2018-06-14
CO7240394A2 (es) 2015-04-17
CN107267460A (zh) 2017-10-20
KR101710487B1 (ko) 2017-02-27
IL274266B (en) 2021-04-29
ES2718346T3 (es) 2019-07-01
DOP2014000298A (es) 2015-03-31
EA201492183A1 (ru) 2015-06-30
IL254560A0 (en) 2017-11-30
US20160053238A1 (en) 2016-02-25
CL2014003568A1 (es) 2015-04-24
SG10201509397SA (en) 2015-12-30
BR112014032560B1 (pt) 2022-04-26
US9150841B2 (en) 2015-10-06
JP2015521848A (ja) 2015-08-03
AU2018200710A1 (en) 2018-02-22
IL236343A0 (en) 2015-02-26
AU2016200460A1 (en) 2016-02-18
AU2018200710B2 (en) 2019-11-14
IL254560B (en) 2020-05-31
GT201400302A (es) 2019-05-22
MX2015000189A (es) 2015-04-08
CA2877521A1 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
BR112014032560A2 (pt) células para produzir iduronato-2-sulfatase recombinante
BR112014032544A2 (pt) método para produzir iduronato-2-sulfatase recombinante
MX2012001742A (es) Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
BR112013017884A2 (pt) varredura de microcolônia encapsulada com gel
BR112012007854A2 (pt) metodos de produção de glicoproteínas em culturas de células de mamíferos usando glicocorticoides
WO2011091350A3 (en) Methods & compositions for improving protein production
EA201171018A1 (ru) Биореактор для культивирования клеток млекопитающих
MX2013006234A (es) Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero.
BR112014026206A2 (pt) sistemas e métodos celulares para melhorar a síntese de ácidos graxos através da expressão da desidrogenase
TR201903066T4 (tr) E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi.
MX2015007361A (es) Produccion mediada por la proteina portadora de acilo de los derivados de acidos grasos.
WO2012031263A3 (en) Cell culture system for bioreactor scale-up of cells
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
MX2015012875A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
BR112014015933A2 (pt) métodos e materiais para reduzir a degradação das proteínas recombinantes
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof
MY182946A (en) Production of organic acids by fermentation at low ph
BR112014003841A2 (pt) estratégia de múltiplas cópias para produção em alto título e alta pureza de proteínas de múltiplas subunidades tal como anticorpos em micróbios transformados tal como pichia pastoris
CA2830600C (en) Compositions and methods for enhancing the pluripotency of stem cells
BR112014019578A2 (pt) Proteína, molécula de dna, células eucarióticase de levedura geneticamente modificada, usos de proteína, de molécula de dna e de células eucarióticas e processos de produção de etanol e de geração de produto de fermentação
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
WO2012103263A3 (en) Compositions and methods for malate and fumarate production

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/06/2013, OBSERVADAS AS CONDICOES LEGAIS.